Despite positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from managed care entities. These companies are typically erecting obstacles to coverage, such as steep expense requirements and prior authorization that limit patient opportunity. Analysts i